Ischemia Care

Company Overview

Ischemia Care (ISC) is a “clinical stage” “capital efficient” pioneer in the field of stroke engaged in diagnostic development, laboratory testing, precision medicine, and bioinformatics to improve patient outcomes and reduce healthcare costs. The goal of ISC is to become the standard of care blood test for stratifying all stroke and TIA patients so that they can receive optimal clinical care.  This technology can also be use as a tool to develop new treatment regimens, therapeutics, point of care diagnostics, and interventional devices. Initial adoption will help further stratify the 30%-40% of ischemic strokes currently diagnosed as “cryptogenic” or unknown cause.

History and Milestones

ISC was founded in 2009 and has established a CLIA laboratory in Ohio, accumulated 1,000+ patient samples of human clinical data and a total of $3.7M in funding to date ($2.3M in equity funding, a $0.5M grant from the Cleveland Clinic’s Global Cardiovascular Innovation Center , and a $0.9M loan from the State of Ohio ). Additional progress includes (1) outstanding management team, scientific and commercial advisors, (2) Major clinical trial NCT02014896 (BASE) currently enrolling at leading Primary Stroke Centers, (3) strategic relationships (Medtronic, Affymetrix), (4) patent filings and license agreements, and (5) well vetted regulatory and reimbursement strategies.


Congress passed the Clinical Laboratory Improvement Amendments (CLIA) in 1988 establishing quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was perform.

Ohio startup looks to commercialize blood test for stroke cause.

Stroke diagnosis startup IschemiaCare gets nearly $1M Ohio loan

IschemiaCare Partners With Medtronic and Affymetrix on Stroke Dx